Volpe, S.; Lisco, G.; Fanelli, M.; Racaniello, D.; Colaianni, V.; Triggiani, D.; Donghia, R.; Crudele, L.; Rinaldi, R.; Sabbà , C.;
et al. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients 2022, 14, 4673.
https://doi.org/10.3390/nu14214673
AMA Style
Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, Donghia R, Crudele L, Rinaldi R, Sabbà C,
et al. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients. 2022; 14(21):4673.
https://doi.org/10.3390/nu14214673
Chicago/Turabian Style
Volpe, Sara, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Domenico Triggiani, Rossella Donghia, Lucilla Crudele, Roberta Rinaldi, Carlo Sabbà ,
and et al. 2022. "Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study" Nutrients 14, no. 21: 4673.
https://doi.org/10.3390/nu14214673
APA Style
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà , C., Triggiani, V., De Pergola, G., & Piazzolla, G.
(2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients, 14(21), 4673.
https://doi.org/10.3390/nu14214673